Recent Quotes (30 days)

You have no recent quotes
chg | %

Hemostemix Inc  

(Public, CVE:HEM)   Watch this stock  
Find more results for CVE:TIK.P
0.170
-0.020 (-10.53%)
Sep 26 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.17 - 0.17
52 week 0.12 - 0.73
Open 0.17
Vol / Avg. 6,400.00/48,996.00
Mkt cap 13.70M
P/E     -
Div/yield     -
EPS -0.05
Shares 67.86M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -751.88% -168.21%
Return on average equity - -223.65%
CDP Score - -

Address

1015 4 St SW Suite 730
CALGARY, AB T2R 1J4
Canada
+1-587-3514393 (Phone)

Website links

Description

Hemostemix Inc. is a clinical-stage biotechnology company. The Company's principal business is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions, including critical limb ischemia (CLI). The Company's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of CLI. ACP-01 is in a Phase II clinical trial in Canada, South Africa and the United States. The Company also focuses on developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs) and neural cell precursors (NCPs). It operates in Canada and Israel. The Company has approximately 2,200 square foot research and manufacturing facility in Ness Ziona, Israel. Hemostemix Limited is the subsidiary of the Company.